Zydus gets FDA green light for drugs to treat diabetes, shingles
Zydus Lifesciences, a subsidiary of Zydus Pharmaceuticals US, has received two tentative FDA approvals, one for treating type 2 diabetes and the other.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Zydus Lifesciences, a subsidiary of Zydus Pharmaceuticals US, has received two tentative FDA approvals, one for treating type 2 diabetes and the other.
The USFDA has granted Zydus Lifesciences Limited ātentative approvalā to market Levomilnacipran extended-release capsules in 20 mg, 40 mg, 80 mg, and 120.
USFDA approves Zydus Lifesciences anti-fungal injection HQ Team October 26, 2022: Zydus Lifesciences announced that it had received final approval from the USFDA.